Skip to main content

Treating Bipolar 1 Disorder

By: 3BL Media

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

SOURCE: Alkermes

DESCRIPTION:

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Tweet me: .@Alkermes has created a new infographic from findings with @HarrisPoll and @DBSAlliance on what healthcare providers (HCPs) had to say about treating individuals with #bipolar 1 disorder: https://bit.ly/3FPKj8a

KEYWORDS: NASDAQ: ALKS, Alkermes

Text: Treating Bipolar 1 Disorder, Healthcare Professionals Share Perspectives on Providing Care for People Living with Bipolar 1 Disorder

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.69
-10.30 (-4.42%)
AAPL  275.91
-0.58 (-0.21%)
AMD  192.50
-7.69 (-3.84%)
BAC  54.94
-0.44 (-0.79%)
GOOG  331.33
-2.01 (-0.60%)
META  670.21
+1.22 (0.18%)
MSFT  393.67
-20.52 (-4.95%)
NVDA  171.88
-2.31 (-1.33%)
ORCL  136.48
-10.19 (-6.95%)
TSLA  397.21
-8.80 (-2.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.